WebApr 6, 2024 · CStone Pharmaceuticals Announces NMPA Accepts the Supplemental Biologics License Application for Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma CI Summary WebPipeline-CStone Pharmaceuticals. We focus on immuno-oncology and precision medicine with a well-balanced oncology portfolio of 15 innovative assets. Currently, CStone has received 10 NDA approvals for its 4 …
CSTONE PHARMACEUTICALS : 2616 Stock Price
WebWilshire Pharmaceuticals utilizes global partnerships and networks for the research, development and manufacturing of key generic products for the U.S. market. These extensive relationships have resulted in a pipeline and product development strategy surrounding multiple therapeutic categories and indications. WebMar 27, 2024 · CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, … incentive\u0027s wn
CSTONE PHARMACEUTICALS : Stock Market News and …
WebMar 31, 2024 · CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs ... WebFeb 17, 2024 · CStone Pharma, a Suzhou oncology company, plans to raise $304 million in its Hong Kong IPO at a valuation of $1.5 billion (see story). Even though CStone is just two and one-half years old, it has ... WebMOBVISTA INC. : Vorstellung des Unternehmens MOBVISTA INC., Aktionäre, Vorstände und Berufsbeschreibung, Finanzstärkerating, offizielle Mitteilungen, Kontaktdaten ... incentive\u0027s wk